Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

This study has been completed.
Sponsor:
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00108290
First received: April 14, 2005
Last updated: April 2, 2008
Last verified: April 2007
  Purpose

In men with prostate cancer who do not have evidence of spread to bone or other sites on computed axial tomography (CAT) scan/bone scan but are still at significant risk of failing treatment with surgery or radiation alone, a combination of chemotherapy and hormone therapy is being given for 6 months followed by surgery to remove the prostate.


Condition Intervention Phase
Prostate Cancer
Drug: Chemotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Chemohormone Therapy Prior to Prostatectomy in High Risk Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Study Start Date: April 2004
Estimated Study Completion Date: March 2007
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • High risk prostate cancer without evidence of bone metastasis.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00108290

Locations
United States, Maryland
VA Maryland Health Care System
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00108290     History of Changes
Other Study ID Numbers: CLIN-003-02F
Study First Received: April 14, 2005
Last Updated: April 2, 2008
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Prostate cancer
chemotherapy
hormone therapy
surgery
PSA
Gleason score

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on April 23, 2014